Across TCGA pan-cancer cohorts, RNASEH2C Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RNASEH2C data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RNASEH2C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNASEH2C expression acts as an unfavorable survival marker.
CESC are the cancer types where RNASEH2C Mutation most reproducibly stratifies survival.